Published in Vaccine Weekly, September 22nd, 2004
"We conducted a phase 1 study of nine pediatric patients with recurrent brain tumors using monocyte-derived dendritic cells pulsed with tumor RNA to produce antitumor vaccine (DCRNA ) preparations. The objectives of this study included establishing safety and feasibility and measuring changes in general, antigen-specific, and tumor-specific immune responses after DCRNA . Dendritic cells were derived from freshly isolated monocytes...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.